CD14 Antibody
Cat# OAEE00640
Size : 100tests(T100)
Brand : Aviva Systems Biology
Contact local distributor :
Phone : +1 850 650 7790
| Datasheets/Manuals | Printable datasheet for CD14 Antibody |
|---|
| Predicted Species Reactivity | Human|Non-human Primate |
|---|---|
| Product Format | Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide |
| Clonality | Monoclonal |
| Clone | MEM-15 |
| Isotype | IgG1 |
| Host | Mouse |
| Conjugation | PerCP |
| Application | FC |
| Reconstitution and Storage | 2°C to 8°C |
| Immunogen | A crude mixture of human urinary proteins precipitated by ammonium sulphate from the urine of a patient suffering from proteinuria. |
| Purification | Purified by size-exclusion chromatography |
| Concentration | 10 ul / test |
| Specificity | The antibody MEM-15 reacts with CD14, a 53-55 kDa GPI (glycosylphosphatidylinositol)-linked membrane glycoprotein expressed on monocytes, macrophages and weakly on granulocytes; also expressed by most tissue macrophages. The antibody MEM-15 also reacts with soluble forms of CD14 found in serum and in the urine of some nephrotic patients. HLDA III; WS Code M 252 HLDA IV; WS Code M 113 HLDA IV; WS Code NL 90 HLDA IV; WS Code T 53 HLDA V; WS Code M MA086 HLDA VI; WS Code M MA94 |
| Formulation | PerCP |
| Storage Buffer | The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent. |
| Reference | Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT: Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood. 1997 Oct 15;90(8):3187-94. Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J: Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med. 2002 Oct 21;196(8):1017-24. Funda DP, Tucková L, Farré MA, Iwase T, Moro I, Tlaskalová-Hogenová H: CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect Immun. 2001 Jun;69(6):3772-81. Bazil V, Horejsi V, Baudys M, Kristofova H, Strominger JL, Kostka W, Hilgert I.: Biochemical characterization of a soluble form of the 53-kDa monocyte surfaceantigen. Eur J Immunol. 1986 Dec;16(12):1583-9. Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989). Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997). Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995). Leukocyte Typing III., McMichael A. J. et al (Eds.), Oxford University Press (1987). Fernández-Real JM, Broch M, Richart C, Vendrell J, López-Bermejo A, Ricart W: CD14 monocyte receptor, involved in the inflammatory cascade, and insulinsensitivity. J Clin Endocrinol Metab. 2003 Apr;88(4):1780-4. Asai Y, Makimura Y, Kawabata A, Ogawa T: Soluble CD14 Discriminates Slight Structural Differences between Lipid As That Lead to Distinct Host Cell Activation. J Immunol. 2007 Dec 1;179(11):7674-83. Lodrup Carlsen KC, Granum B: Soluble CD14: role in atopic disease and recurrent infections, including otitismedia. Curr Allergy Asthma Rep. 2007 Nov;7(6):436-43. Juan TS, Hailman E, Kelley MJ, Wright SD, Lichenstein HS: Identification of a domain in soluble CD14 essential for lipopolysaccharide (LPS) signaling but not LPS binding. J Biol Chem. 1995 Jul 21;270(29):17237-42. |
|---|---|
| Gene Symbol | CD14 |
| Gene Full Name | CD14 molecule |
| Alias Symbols | monocyte differentiation antigen CD14, myeloid cell-specific leucine-rich glycoprotein. |
| NCBI Gene Id | 929 |
| Protein Name | Monocyte differentiation antigen CD14 |
| Description of Target | Coreceptor for bacterial lipopolysaccharide (PubMed:1698311, PubMed:23264655). In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS) (PubMed:20133493, PubMed:23264655). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:8612135). Acts as a coreceptor for TLR2:TLR6 heterodimer in response to diacylated lipopeptides and for TLR2:TLR1 heterodimer in response to triacylated lipopeptides, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway (PubMed:16880211). Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-) (PubMed:23880187). |
| Uniprot ID | P08571 |
| Protein Accession # | NP_000582.1; NP_001035110.1; NP_001167575.1; NP_001167576.1 |
| Nucleotide Accession # | NM_000591.3; NM_001040021.2; NM_001174104.1; NM_001174105.1 |
